Composition
Active ingredient: dry extract of hiporamine (sea buckthorn leaves dry extract, Hippophae rhamnoides L.), (6.5:1), extractant ethanol – 70%) with a content of the sum of tannins in terms of casuarinine and absolutely dry matter of 60%;
1 tablet contains 20 mg of dry extract of hyporamine;
Excipients: sucrose, cocoa powder (cocoa bean powder), vanillin, carmellose sodium, calcium stearate.
Dosage form
Sublingual pills.
Main physicochemical properties: tablets are round, biconvex, with a notch, from light gray or light gray with a pink tint to light brown with dark and light inclusions.
Pharmacotherapeutic group
Other antiviral agents. ATX code J05A X.
Pharmacological properties
Hyporamine – a dry purified extract from the leaves of sea buckthorn-like (Hippophae rhamnoides L.) – is a polyphenolic complex of haloellagotannins, the biologically active components of which are hydrolyzed tannins, which have common structural elements in the form of glucose-halo and hexahydroxyphenol residues.
Hyporamine exhibits high antiviral activity against various strains of influenza A and B viruses, adenoviruses, paramyxoviruses, herpes simplex viruses, shingles, cytomegalovirus (CMV), respiratory syncytial virus (RS-virus). The inhibitory effect of the drug on the reproduction of viruses is manifested in the early stages of their development. One of the mechanisms of action of the drug is the inhibitory effect on viral neuraminidase.
Hyporamine induces interferon production in blood cells in vitro and increases the content of interferon in the blood of patients.
The drug also has a moderate antimicrobial effect in vitro against gram-positive (Staphylococcus aureus) and gram-negative bacteria (Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa), tuberculous mycobacteria (Mycobacterium tuberculosis), candida (Candida albicans) and some mycelial fungi (Microsporum canis).
Indication
As a therapeutic and prophylactic agent for influenza (A and B), parainfluenza, respiratory syncytial virus, viral, adenovirus and other acute respiratory viral infections; tonsillitis occurring against the background of acute respiratory viral diseases (complex therapy); for acute and recurrent forms of herpes simplex of extragenital and genital localization, for shingles, chickenpox and cytomegalovirus infection.
Application
The drug is taken orally.
Treatment. 1 tablet is kept in the mouth until completely dissolved. Adults and children over 12 years of age are prescribed 1 tablet 4-6 times a day, children aged 6-12 years – 1 tablet 3-4 times a day, children 3-6 years – ½ tablet 2-4 times a day.
Duration of use – from 3 days to 3 weeks, depending on the nosological form of the disease.
If Orebru is started immediately at the first symptoms of SARS and flu, it is enough to take it for 7 days, if the intake is started after the 2-3rd day from the onset of the disease – the duration of the intake lasts 14 days, if complications develop and for the purpose of prevention, the use of the drug should be continued until the 21st day.
In chickenpox, shingles, herpesvirus and CMV infections, the duration of use depends on the severity of the process and is 3-10 days for mild forms of the disease. In severe and recurrent forms of the disease, the minimum course of treatment is 2-3 weeks. Repeated courses of treatment are advisable.
For prevention during a flu outbreak, the drug is taken according to age-appropriate dosage for up to 3 weeks.
Contraindication
Hypersensitivity to the components of the drug. Sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.
Side effects
Allergic reactions are possible.
If any adverse reactions develop, treatment should be discontinued and a doctor should be consulted.
Special instructions
It is necessary to prescribe it as early as possible in the course of the disease.
Use with caution in diabetes.
1 tablet of the drug contains 0.5539 g of carbohydrates, which corresponds to 0.046 bread units. Patients with diabetes should take the drug after consulting a doctor.
Use during pregnancy and breastfeeding. Safety and efficacy have not been established, so do not use.
Children. The drug is used in children aged 3 years and older.
The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.
Interactions
It is possible to use the drug in combination with other medications (antimicrobials, synthetic antiviral agents, agents for symptomatic therapy).
Overdose
To date, no cases of drug overdose have been registered.
With prolonged use in doses exceeding those specified in the instructions, increased blood clotting is possible.
Treatment is symptomatic.
Packaging
10 tablets in a blister, 1 or 2 blisters in a cardboard pack; 20 tablets in a blister, 1 blister in a cardboard pack.
Storage conditions
In the original packaging at a temperature not exceeding 25 °C.
Reviews
There are no reviews yet.